[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ortega-Rivera et al., 2021 - Google Patents

Trivalent subunit vaccine candidates for COVID-19 and their delivery devices

Ortega-Rivera et al., 2021

View PDF
Document ID
3657872743615951168
Author
Ortega-Rivera O
Shin M
Chen A
Beiss V
Moreno-Gonzalez M
Lopez-Ramirez M
Reynoso M
Wang H
Hurst B
Wang J
Pokorski J
Steinmetz N
Publication year
Publication venue
Journal of the American Chemical Society

External Links

Snippet

The COVID-19 pandemic highlights the need for platform technologies enabling rapid development of vaccines for emerging viral diseases. The current vaccines target the SARS- CoV-2 spike (S) protein and thus far have shown tremendous efficacy. However, the need …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)

Similar Documents

Publication Publication Date Title
Ortega-Rivera et al. Trivalent subunit vaccine candidates for COVID-19 and their delivery devices
Shin et al. COVID-19 vaccine development and a potential nanomaterial path forward
Chung et al. COVID-19 vaccine frontrunners and their nanotechnology design
Kang et al. Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates
Ramesh et al. Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy
Conte et al. Vaccines against coronaviruses: the state of the art
Valdes-Balbin et al. Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines
Jearanaiwitayakul et al. Intranasal administration of RBD nanoparticles confers induction of mucosal and systemic immunity against SARS-CoV-2
Royal et al. Development of a SARS-CoV-2 vaccine candidate using plant-based manufacturing and a tobacco mosaic virus-like nano-particle
Nel et al. Nano-enabled COVID-19 vaccines: meeting the challenges of durable antibody plus cellular immunity and immune escape
Lee et al. Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages
Volpatti et al. Polymersomes decorated with the SARS-CoV-2 spike protein receptor-binding domain elicit robust humoral and cellular immunity
Kozak et al. The integrated consideration of vaccine platforms, adjuvants, and delivery routes for successful vaccine development
Kraft et al. Antigen-and scaffold-specific antibody responses to protein nanoparticle immunogens
Yaqinuddin et al. Effect of SARS-CoV-2 mutations on the efficacy of antibody therapy and response to vaccines
Mathew et al. Platforms exploited for SARS-CoV-2 vaccine development
Ortega-Rivera et al. Cowpea mosaic virus nanoparticle vaccine candidates displaying peptide epitopes can neutralize the severe acute respiratory syndrome coronavirus
Lamontagne et al. Vaccination strategies based on bacterial self-assembling proteins as antigen delivery nanoscaffolds
US20240108716A1 (en) Monovalent and multivalent vaccines for prevention and treatment of disease
Wei et al. An apoferritin–Hemagglutinin conjugate vaccine with encapsulated nucleoprotein antigen peptide from influenza virus confers enhanced cross protection
Lam et al. Artificial cell membrane polymersome-based intranasal Beta spike formulation as a second generation Covid-19 vaccine
Liu et al. Nanoparticles and antiviral vaccines
Pandey et al. Protein nanoparticles as vaccine platforms for human and zoonotic viruses
Zhuang et al. Harnessing T-cells for enhanced vaccine development against viral infections
Choi et al. Bolstering components of the immune response compromised by prior exposure to adenovirus: guided formulation development for a nasal Ebola vaccine